ALL — The Allstate Corporation

Price action and news flow are bullish even though the sell-side rating is not. As of 2026-09-13 the stock was up 23.06% over six months and 14.47% over three months, driven by a Q2 2026 (reported 2026-08-05) adjusted EPS of $8.99 versus ~$6.06 consensus and revenue of $18.60B (+11.8% YoY), with net investment income near $1.0B. Recent analyst actions skew positive (Zacks upgrade to Strong Buy, JPMorgan to $292 Overweight), yet the formal consensus is still 'Hold' (17 buy / 23 hold / 4 sell) with a $268 average target - so enthusiasm is real but not universal. The past month (-0.83%) and past week (-2.26%) show the tape cooling off after the post-earnings run rather than breaking down.

This is a genuine cyclical inflection, not a blip. Revenue climbed from $14.31B in Q3 2023 to $16.55B in Q2 2025 to $18.60B in Q2 2026, and YoY growth is re-accelerating: +1.5% in Q4 2025, +4.2% in Q1 2026, +12.4% in Q2 2026. Operating income shows the recovery even more starkly: -$21M in Q3 2023, $430M in Q2 2024, then $4.82B and $4.92B in Q3/Q4 2025, and $4.24B in Q2 2026 (+57% YoY). Diluted EPS went from -$0.16 (Q3 2023) to $1.13 (Q2 2024) to $2.11 (Q1 2025) to $7.76 (Q2 2025) to $12.51 (Q2 2026). Margins: operating margin of 22.8% in Q2 2026 versus 16.3% in Q2 2025, but below the 28.2% and 29.6% prints in Q3/Q4 2025 - margin is up sharply YoY yet has already rolled off its late-2025 peak, which is precisely the 'peak margin' debate the sell-side is having. Stockholders' equity compounded from $14.6B (Q3 2023) to $33.7B (Q2 2026). The honest read: the auto underwriting recovery is real and largely structural, but the current earnings level is flattered by prior-year reserve releases and a benign catastrophe year, and the accruals ratio of just 0.51% confirms reported profit is running only slightly ahead of operating cash flow.

Fair, with a modest cheap tilt on forward numbers. As of 2026-09-13 the stock traded at 5.0x trailing EPS of $51.99 - versus a 3-year average trailing P/E of 7.77x - which screams cheap until you notice that analysts expect next-FY EPS of $35.33, a ~32% decline. On that forward figure the P/E is 7.18x, roughly in line with the company's own trailing average and roughly a third below the P&C peer group. Supporting the floor: 1.93x book against a 33.6% trailing ROE and 20.8% ROIC, with debt/equity of only 0.22x. The caution: P/S of 0.944 is already a premium to the 5-year average of 0.74, meaning the market is paying up for revenue, not just earnings. The PEG of 0.037 is mathematically meaningless here and should be ignored.

The market is not paying for the beat it just got - it is pricing in mean reversion. At $253.71, the stock capitalizes the $35.33 next-FY consensus at only 7.2x, a multiple that assumes today's ~$8-9 quarterly adjusted EPS is closer to a ceiling than a run-rate. That creates an asymmetric setup: if Allstate simply holds the current run-rate (four quarters at ~$8.50-9.00), the stock is underpricing the earnings stream and re-rates toward 8.5-9x, and the bull case is that consensus estimates are lagging the repricing already visible in the auto book. The bear case is equally specific: if prior-year reserve releases fade and the cat season normalizes, the $12.51 GAAP quarter becomes an outlier and the forward estimate gets cut again - in which case 7x earnings was the right price. Watch whether forward EPS estimates are revised up or down over the next two quarters; that revision direction, not the headline P/E, is the real signal.

Neutral-to-constructive consolidation inside a strong uptrend. As of 2026-09-13, RSI(14) was 45.74 - firmly mid-range, neither overbought nor oversold - with the price at $253.71 sitting 1.6% below its 20-day (~$257.83) and 1.56% below its 50-day (~$257.73) simple moving averages, but 13.99% above its 200-day (~$222.57). Returns of -2.26% (1 week), -0.83% (1 month), +14.47% (3 months) and +23.06% (6 months) describe a stock digesting a big move rather than one that has broken trend. Entry implication: there is no urgency here. A push back above $257-258 would confirm trend resumption, while a pullback toward the 200-day near $222-225 would be the higher-reward entry; the current mid-range RSI offers no timing edge either way.

• Interest rates: elevated yields have been a direct earnings tailwind, driving net investment income to roughly $1.0B in Q2 2026. A rapid rate-cut cycle would compress reinvestment yields and remove a meaningful part of the earnings beat, while rising rates would boost new-money yields but mark down the existing bond book.
• Auto insurance pricing cycle: the 2022-2025 industry rate increases have restored auto underwriting margins, but premium rate inflation is now cooling and competition (notably from Progressive) is returning. The next phase is about retention and disciplined underwriting rather than rate-driven margin expansion.
• Catastrophe and weather volatility: a relatively benign 2026 storm season through mid-year has kept catastrophe losses manageable and flattered results. Hurricanes, wildfires and convective storms remain a structural, non-diversifiable risk for a national personal-lines writer.
• Social and repair-cost inflation: auto parts, labor, medical and litigation costs drive severity trends. If severity re-accelerates faster than pricing, the hard-won margin improvement erodes quickly.
• Regulation: state insurance departments approve rate filings and can push back after a period of unusually large consumer rate increases, capping Allstate's ability to re-price if loss costs deteriorate.

• Q3 2026 earnings, tentatively after the close on Wednesday, November 4, 2026 - the key read on catastrophe losses, auto policy retention and buyback commentary.
• Further favorable prior-year reserve development, which has been a material contributor to recent EPS beats and would support consensus estimate revisions higher.
• Capital return: continued share repurchases (which are compounding book value per share) and any dividend increase.
• Sell-side estimate revisions and potential rating upgrades - the consensus is still a 'Hold' with only one Strong Buy, so the rating distribution has room to improve if forward EPS holds.
• A severe hurricane or wildfire event, or an accelerated rate-cut cycle, both of which would work against the current narrative.

• Earnings mean reversion: TTM EPS of $51.99 versus a $35.33 next-FY consensus is an implied ~32% decline, and the trailing number is inflated by reserve releases and a benign cat year. The 5.0x trailing P/E is a mirage if that normalization happens.
• Catastrophe exposure: a single major hurricane or wildfire season can produce multi-billion-dollar losses and wipe out a quarter or more of underwriting profit.
• Competitive pressure in auto: cooling rate inflation plus aggressive competitor spending could pressure retention and force Allstate to trade margin for policy count.
• Reserve adequacy risk: several quarters of favorable prior-year development can reverse; adverse development would hit both earnings and book value simultaneously.
• Valuation already full on sales: P/S of 0.944 versus a 5-year average of 0.74 means the multiple has expanded, leaving less cushion if revenue growth decelerates.

Allstate is a high-quality, low-beta (0.15) personal-lines insurer that has just posted a genuine earnings inflection - 33.6% trailing ROE, 20.8% ROIC, 0.22x debt/equity, and 12% revenue growth in Q2 2026 - at 7.2x next-FY EPS and 1.9x book. The catch is that the trailing 5.0x P/E is built on earnings the sell-side already expects to fall roughly a third, so you are not buying a 5x earnings stock; you are buying a ~7x earnings stock whose next two quarters determine whether $35 EPS is a floor or a waypoint. I would not chase it at $253.71 given RSI 45.7 and a stalling tape, but the risk/reward is reasonable and a pullback toward the 200-day near $222-225 would make it genuinely attractive. This is analysis, not personalized financial advice.

Applied a justified 8.5x forward P/E to the next-FY consensus EPS of $35.334, producing roughly $300. The 8.5x is a modest premium to Allstate's own 3-year average trailing P/E of 7.77x and a large discount to the P&C peer group (~11-14x), justified by 20.8% ROIC, 33.6% trailing ROE, 0.22x debt/equity, a 0.15 beta and a defensive demand profile, then tempered for catastrophe exposure and the fact that trailing earnings quality is partly reserve-release driven.